Genmab — August 2017
-
nej ingen penge til Genmab
-
kun deling af omkostninger og gevinster
-
ja okay. Men lad os håbe at Tiso kommer på markedet en dag og leverer en god omsætning, og så får Genmab 50 % af gevinsten. Ikke dårligt.
-
samtidig viser SGEN med dette at de tror på tisotumab. Altså en tillidserklæring til tiso af en anden part end Genmab. Positivt
-
Har denne været nævnt? https://wallstreetwires.com/genmab-big-us-pharma-make-move-latest-drug-trial-success/
-
Utroligt. Så er vi i rødt igen. https://www.google.com/finance?q=CPH%3AGEN&ei=e1SlWeCkE8OCsAHOx4yYDQ
-
Halvgammelt nyt men alligevel lidt apropos: Aug. 1, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a biotechnology company, today announced that it has signed definitive agreements to purchase Bristol-Myers Squibb’s pharmaceutical manufacturing facility in Bothell, Washington. The facility, known as the Monte Villa Parkway Research Center, is a 51,000 square foot state-of-the art manufacturing and laboratory space built in 2014.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind